



Buccal Drug Delivery System of Risperidone- Formulation and in Vitro, in Vivo Evaluation

Soudam Sai Sree¹, Ankit Singh², Gollapudi Rajesh^{3*}

¹Research Scholar, Department of Pharmacy, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India, 333001, ORCID ID: 0009-0009-1640-2964

²Research Guide, Department of Pharmacy, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India, 333001, ORCID ID: 0009-0004-9747-6052

^{3*}Research Co Guide, Department of Pharmacy, Shri Jagdishprasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India, 333001, Email: rajeshgollapudi123@gmail.com, ORCID ID: 0009-0004-5917-3413

Abstract

Bio-adhesive buccal-delivery of drugs is one of alternative to the oral route of drug administration, particularly drugs that are having poor-bioavailability (BA) a first pass effect. The bioavailability of such drugs may be significantly improved if delivered through the buccal route. Risperidone is used widely for treating hypertension. The drug is well absorbed from the gastrointestinal tract but its bioavailability is low (30- 50%) due to extensive first pass metabolism. Since the buccal route bypasses the first-pass effect, the dose of Risperidone could be reduced by 50%. The physicochemical properties of Risperidone, its suitable half-life (3-7 h) a low molecular weight (196.64) used the oral route for small dose. Risperidone buccal muco-adhesive tablets were prepared by direct compression technique, using carbopol 934P, HPMC K4M as muco-adhesive polymers. Prepared formulations were evaluated for physicochemical characteristics, ex-vivo residence time a in-vitro release studies. Further, in vivo pharmacokinetic studies were performed in pigs.

The results of all the prepared tablets were within the acceptable pharmacopeial limits. The swelling a bio-adhesive strength values were increased a drug-release (DR) was decreased with increasing the polymer concentration. From the results, tablets with Na CMC (F2) exhibited better release, which may be due to the hydrophilicity a water uptake by the tablet a were considered as optimized formulation. The optimized formulation F2 developed with HPMC K4M released $99.62 \pm 2.24\%$ in 6 h. The release mechanism from kinetic methods suggests that, the drug-release (DR) follows zero-order kinetics with diffusion mechanism. The drug permeation was found to be 89.88% , while the flux a permeability coefficient of risperidone was calculated to be $0.668 \text{ mg h}^{-1} \text{ cm}^{-2}$ a 0.056 cm h^{-1} , respectively. DSC studies confirming that there was no interaction between the drug and other excipients. 3.09-folds enhance bio-adhesive in the oral bioavailability (BA) of risperidone from buccal tablet when compared with immediate release marketed formulation (Nepresol®). Thus, the buccal tablets of Risperidone showed enhanced BA a which was confirmed by in-vivo studies.

Keywords: Risperidone, Buccal drug delivery system, Bioavailability, RP-HPLC

Introduction

As of late the enthusiasm for novel route of drug administration happens from their capacity to upgrade the bioavailability of drugs. Drug delivery by means of buccal route, utilizing bio-adhesive dose frames offers such a novel route of drug administration. Buccal-delivery includes administration of wanted drug through the buccal mucosal film coating of oral-mucosa. For a long time, treatment of an intense infection or an interminable disease has been for the most part achieved by conveying drugs utilizing different pharmaceutical measurements shapes, including tablets, containers, pills, suppositories, creams, salves, fluids, mist concentrates an injectable as transporters. Among different routes of drug delivery oral route is maybe the most wanted to the patient the clinician alike. Anyway, this route shows a few issues for a couple of drugs. The compounds in the GI liquids, GIT-pH conditions the proteins to GIT films are a couple of variables in charge of the bioavailability issues. The blood that depletes the GIT conveys the drug straightforwardly to the liver prompting first-pass digestion bringing about poor-bioavailability. The inalienable issues related with the drug at times can be fathomed by altering the detailing or by changing the routes of administration. Parenteral, mucosal transdermal routes evade hepatic first-pass digestion offer elective routes for the fundamental delivery of drugs.

As of late, the enthusiasm for novel-routes of drug-administration happens from their capacity to improve the bioavailability of drugs. Drug-delivery by means of the buccal route utilizing bio adhesive measurement shapes offers such a novel route of drug administration. Broad first-pass digestion a drug corruption in the cruel gastrointestinal coition can be dodged by overseeing the drug by means of buccal route. Buccal-delivery includes administration of wanted drug through the buccal mucosal film covering of oral pit. The mucosal coating of oral pit offers some unmistakable favorable circumstances. It is luxuriously vascularized a progressively available for the administration a evacuation of a measurement frame. Furthermore, Buccal drug delivery has high patient agreeableness contrasted with other non-oral routes of drug administration

[illegible]

Sodium CMC	25	50	75	-	-	-	-	-	-
HPMC K4M	-	-	-	25	50	75	-	-	-
Sodium Alginate	-	-	-	-	-	-	25	50	75
MCC	105	80	55	105	80	55	105	80	55
Magnesium stearate	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
Talc	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
Total weight (mg)	185	185	185	185	185	185	185	185	185

Micromeritic properties

The pre-compression properties of Risperidone ble was determined by subjected to angle of repose, bulk density, tapped density, Carr's iex a Hausner's ratio as per the procedures described in sec

Results And Discussion


The standard graph of Risperidone showed good linearity with R2 value of 0.993 in the linearity range of 5-30 μ g/mL in pH 6.8 phosphate-buffer, which indicates that it obeys "Beer- Lamberts" law.

Solubility studies:

The solubility study was conducted in distilled water, 0.1N HCl a pH 6.8 phosphate-buffer because the average pH value of oral cavity is 6.6. Solubility of Risperidone was to be 0.83 ± 0.04 , 4.72 ± 0.71 a 11.3 ± 1.04 mg/mL in water, 0.1N HCl a pH 6.8 phosphate-buffers. Risperidone is showed more solubility in pH 6.8 phosphate-buffers. Hence, pH 6.8 phosphate-buffer was selected as a solvent for standard graph a as a medium for in-vitro studies

Compatibility Studies

The DSC is a useful tool for determining the drug excipient interaction for the development formulation.






Figure 1: DSC thermogram of A) pure drug, B) pure HPMC K4M, C) physical mixture of drug and HPMC K4M (1:1) and D) optimized formulation (F2)

The thermal properties of the drug and the blend of drug and excipients are of vital importance since this can study the compatibility among various segments of the details. The DSC thermograms of unadulterated Risperidone indicated exothermic crest at a temperature of 164.7°C, which is comparing to its softening territory (163.1 – 168.9°C). the unadulterated HPMC K4M polymer indicated deteriorated exothermic crest at 76.88°C. If there should arise an occurrence of physical blend, the medication demonstrated an exothermic top at 165.3°C a polymer at 75.77°C. The upgraded definition demonstrated medication top at 157.7°C a HPMC K4M polymer at 71.77°C, individually. From this perception, there was no association happens among medication and polymer.

Formulation of RISPERIDONE buccal tablets

The mixes for mucoadhesive tablets were portrayed concerning point of rest, mass thickness, tapped thickness, Carr's file, a Hausner's proportion. Point of rest was used 30° a Carr's record esteems were used 15 for the mix of the considerable number of groups showing astounding to great flowability and compressibility. Hausner's proportion was used 1.11 for every one of the bunches demonstrating astounding stream properties.

Table 3: Physical Properties of Pre-compression Blend

Formulation Code	Angle of repose	Bulk density (gm/cm ³)	Tapped density (gm/cm ³)	Carr's index (%)	Hausner's ratio (HR)
F1	36.82 ± 0.19	0.388 ± 1.6	0.426 ± 1.2	16.22 ± 1.4	1.21 ± 0.08
F2	38.35 ± 0.14	0.4222 ± 0.5	0.474 ± 1.8	19.8 ± 1.8	1.24 ± 0.05

F3	39.92 ± 0.24	0.416 ± 0.9	0.456 ± 1.4	17.22 ± 2.5	1.19 ± 0.6
F4	37.10 ± 0.23	0.462 ± 1.2	0.521 ± 1.3	20.60 ± 1.5	1.23 ± 1.8
F5	36.08 ± 0.21	0.503 ± 2.0	0.572 ± 2.0	18.12 ± 2.5	1.2 ± 1.8
F6	38.76 ± 0.15	0.483 ± 0.9	0.592 ± 1.2	19.34 ± 2.0	1.24 ± 0.4
F7	37.12 ± 0.14	0.519 ± 1.6	0.534 ± 0.9	20.2 ± 1.8	1.25 ± 0.8
F8	39.29 ± 0.14	0.524 ± 1.4	0.611 ± 1.2	17.58 ± 2.4	1.22 ± 0.6

Table 4: Physical Properties of Pre-compression Blend

Formulation	Angle of repose (°)	Bulk Density (g/mL)	Tapped Density (g/mL)	Carr's Index (%)	Hausner's ratio
H1	22.360	0.365	0.335	14.36	1.54
H2	30.250	0.353	0.423	13.65	1.83
H3	24.550	0.452	0.489	15.33	1.89
H4	29.350	0.333	0.326	14.56	1.98
H5	22.490	0.329	0.349	14.82	1.91
H6	30.420	0.325	0.415	13.45	1.59
H7	24.630	0.435	0.435	13.66	1.31
H8	22.450	0.329	0.386	12.83	1.64
H9	30.330	0.345	0.382	12.85	1.26

Physical Evaluation Of Buccoadhesive Tablets**Weight variation, Thickness a Hardness**

The values of weight variation a thickness of the tablets (Table 5.4) were found to be within the limits of conventional oral tablets stated in the Indian Pharmacopoeia (IP, 1996). The mass ranged from 172 to 178 mg. Thickness of the tablets varied from 2.22 mm to 2.34 mm. Hardness of the tablets was in the range 3 to 3.5 kg/cm². The mass, thickness a hardness of all compressed tablets were within the limits as per USP.

Table 5: Weight variation, Thickness a Hardness

Formulation	Weight variation (mg)	Thickness (mm)	Hardness (kg/cm ²)
F1	173	2.25±0.16	3.0±0.5
F2	177	2.22±0.13	3.3±0.3
F3	175	2.28±0.14	3.1±0.5
F4	174	2.26±0.16	3.5±0.2
F5	172	2.27±0.15	3.3±0.5
F6	174	2.24±0.25	3.5±0.2
F7	178	2.30±0.14	3.1±0.5
F8	176	2.34±0.17	3.2±0.3
H1	184.5±1.55	2.36±0.16	3.9±0.52
H2	185.5±1.25	2.36±0.13	4.2±0.33
H3	188±1.33	2.32±0.14	4.3±0.55
H4	183.5±1.21	2.33±0.16	3.9±0.27

H5	184.2±1.32	2.38±0.15	4.2±0.51
H6	182.5±1.16	2.35±0.25	4.7±0.26
H7	188.2±1.36	2.36±0.14	4.5±0.51
H8	183.5±1.32	2.32±0.17	4.2±0.33
H9	182.9±1.15	2.31±0.17	4.3±0.36

Friability Assay

The drug content ranged from 95.44 to 102.46. The friability ranged from 0.21 to 0.53. Friability a assay of all compressed tablets were within the limits as per USP. The drug content ranged from in all formulation H1 to H9 was 96.53 to 101.42 at the friability ranged from 0.22 to 0.51. Friability a drug content of all compressed tablets were within the limits as per USP.

The values of friability a drug content of tablets were shown in given Table 5.5.

Table 6: Friability assay of the RISPERIDONE buccal tablets

Formulation	Friability (%)	Drug Content (%)
F1	0.21	95.44
F2	0.45	96.84
F3	0.53	94.56
F4	0.24	97.22
F5	0.31	98.26
F6	0.37	97.33
F7	0.42	102.46
F8	0.29	97.47
H1	0.45	97.65
H2	0.49	96.53
H3	0.52	99.76
H4	0.48	98.32
H5	0.55	99.16
H6	0.48	97.53
H7	0.49	101.42
H8	0.59	97.47
H9	0.55	98.64

Swelling studies:

The bio adhesion a drug-release (DR) profile are needy after swelling conduct of the tablets. Swelling record expand as the load gain by the tablets expand relatively with the rate of hydration. In swelling study, it was discovered that the measure of HPMC K15M assumes an imperative job in swelling of the grid a prompts the medication dispersion. It was seen that swelling rate expand with an expansion in Polymer substance of the readied tablets. Every one of the plans indicated great swelling record in the scope of 11 to 71%. Definition F6 containing carbopol had incited most extreme swelling list.

Table 7: Percentage Swelling Index of RISPERIDONE buccal tablets (mean±SD, n=3)

Formulation	1 hour	2 hour	3 hour	4 hour	5 hour	6 hour
F1	16.01±0.098	25.71±1.10	37±0.74	46.71±1.10	54±0.49	62±0.78
F2	19.12±0.084	28.04±1.51	39±1.03	47.9±1.99	58±1.57	69±2.12
F3	14.98±1.01	23.14±1.33	32±0.91	41.9±1.33	53±1.83	60.5±1.12

F4	11.14± 0.088	21.96± 0.052	29± 1.07	38.5± 1.01	49±1.81	57.4± 1.23
F5	15.36± 0.99	24.16± 1.05	31± 1.70	40.4± 1.21	51±1.03	59.6± 1.34
F6	21.31± 0.65	29.53± 0.78	38± 1.57	49.4± 1.57	59±1.21	71.3± 0.95
F7	17.61± 0.95	28.96± 1.01	37± 1.35	45.0± 0.58	55±1.53	63.2± 1.04
F8	18.66± 1.16	29.56± 1.47	36± 1.02	44.8± 1.99	52±1.73	59.5± 2.01




Figure 2: Percentage Swelling index of RISPERIDONE buccal tablets

Table 8: In-vitro release profiles of RISPERIDONE buccal tablets F1 to F4

Time(h)	% drug-release (DR)			
	F1	F2	F3	F4
0	0	0	0	0
0.5	36.25±2.18	30.31±2.33	27.43±1.26	23.25±1.11
1	50.81±3.22	40.56±2.24	36.31±2.21	30.81±2.15
2	73.12±2.26	58.56±1.31	47.31±2.28	46.43±2.25
3	87.5±1.16	78.75±2.36	60.56±3.17	58.5±2.34
4	98.76±2.19	86.87±1.17	81.87±1.15	75±3.36
5		95.62±3.25	90.62±2.19	88.1±2.17
6		99.62±2.24	96.87±2.17	90.62±3.19




Figure 3: In vitro release profiles of formulations from F1 to F4

Table 9: In-vitro release profiles of RISPERIDONE buccal tablets F5 to F8

Time (h)	% drug-release (DR)			
	F5	F6	F7	F8
0	0	0	0	0
0.5	29.25±1.21	21.25±1.87	17.87±1.03	15.37±0.92
1	42.25±1.11	28.93±2.84	21.93±1.74	21.1±1.07
2	52±2.06	46.43±2.81	37.06±2.06	33.68±1.84
3	73.12±1.88	61.93±3.16	52.06±2.81	43.56±2.74
4	81.87±2.18	79.37±1.84	71.87±1.72	61.37±3.81
5	93.12±1.95	89.37±2.17	81.87±1.99	70.62±2.83
6		99.45±1.84	94.37±1.96	86.25±1.99




Figure 4 In vitro release profiles of formulations from F5 to F8

A perfect controlled-release (CR) system ought to have the capacity to release the medication quickly to achieve the restorative dimension at a quicker rate and keep up this medication level for a delayed timeframe. In vitro tranquilizer release thinks about uncovered that the arrival of valsartan from various definitions changes

with qualities a synthesis of system shaping polymers as appeared in diagrams. The release rate of valsartan diminished with expanding centralization of sodium CMC, HPMC K4 M a sodium alginate in H1 a H9. The most imperative factor influencing the rate of release from the buccal tablets is the medication: polymer proportion. An expansion in optional polymer focus causes an increment in the consistency of the gel a in addition development of a gel layer with a more drawn out dispersion way. Every one of the outcomes were appeared in the in the tables 5.11 to 5.13 a figures 5.7 to 5.9.

The outcomes show that as the convergence of every polymer increments in the individual arrangement, Higuchi dissemination instrument swings to zero-order release profiles. Expanding the convergence of polymer in the definitions demonstrated a continued impact on valsartan release. The quickly hydrating polymer commanded in controlling the arrival of valsartan from the buccal tablets, as observed from the disintegration profiles a dampness ingestion information. Release rate backed off when the convergence of sodium CMC, HPMC K4 M a sodium alginate expanded from the plans H1 a H9. This is on the grounds that as the extent of these polymers in the network expanded, there was an expansion in the measure of water take-up a relatively more noteworthy swelling prompting a thicker gel layer. F6 definitions indicated stretched out medication release up to 6hrs a demonstrated most extreme medication arrival of $98.71 \pm 2.69\%$ a supported up to 6hrs. In light of the medication release thinks about detailing F6 chose as an optimized definition, these are assessed for ex-vivo penetration consider.

Table 10 : In-vitro release profiles of formulations H1 to H3

Time(h)	Cumulative % release		
	H1	H2	H3
0	0	0	0
0.5	38.33 ± 2.26	34.48 ± 1.66	33.15 ± 2.44
1	49.65 ± 1.35	46.55 ± 1.79	42.16 ± 2.29
2	65.34 ± 2.32	59.66 ± 2.51	56.46 ± 1.65
3	81.46 ± 2.31	78.46 ± 2.32	70.75 ± 2.63
4	99.76 ± 2.78	88.43 ± 1.74	78.65 ± 1.72
5		99.33 ± 2.29	89.33 ± 2.25
6			99.84 ± 2.32





Figure 5: In vitro release profiles of formulations from H1 to H3

Table 11: In-vitro release profiles of formulations H4 to H6

Time (h)	Cumulative % release		
	H4	H5	H6
0	0	0	0
0.5	35.33±1.75	32.19±2.36	28.17±2.36
1	51.61±2.36	45.45±1.52	39.92±2.24
2	67.97±2.36	59.71±2.29	52.37±1.66
3	82.97±1.94	71.22±1.35	64.16±1.68
4	91.63±2.45	83.86±2.33	74.32±2.52
5	99.15±2.63	92.66±1.44	86.15±2.42
6		100.52±2.36	99.95±2.36

**Figure 6: In vitro release profiles of formulations from H4 to H6****Table 12: In-vitro release profiles of formulations H7 to H9**

Time (h)	Cumulative % release		
	H7	H8	H9
0	0	0	0
0.5	40.94±2.25	37.62±2.36	33.09±1.36
1	58.86±1.86	54.72±1.52	46.61±2.24
2	73.43±2.36	69.72±2.29	59.17±1.66
3	87.53±1.44	79.49±2.35	73.07±1.99
4	100.33±1.45	91.73±2.33	85.96±1.52
5		99.97±1.44	93.89±2.42
6			100.68±2.45




Figure 7 : In vitro release profiles of formulations from H7 to H9

Kinetics of drug-release (DR) a mechanism:

To know the release mechanism a kinetics of Risperidone, the release information was fitted into scientific models a n , r^2 values for zero order, First order, Higuchi a Peppas models were spoken to in Table 5.14. The peppas display is broadly utilized, when the release instrument isn't outstaing or beyo what one sort of release could be included.

The semi-experimental coition appeared:

$$M_t/M_\infty = k t^n$$

Where, M_t/M_∞ is part of medication released at time ' t ', k speaks to a consistent, a n is the diffusional type, which portrays the sort of release instrument amid the disintegration procedure. For non-fickian release, the estimation of n falls somewhere in the range of 0.5 a 1.0; while in case of fickian dispersion, $n = 0.5$; for zero-arrange release (case II transport), $n = 1$; a for supercase II transport, $n > 1$. The release type " n " values were more prominent than 0.5, which shows that the medication release from every one of the clusters pursued non fickian component. The higher R^2 values for Zero order a Higuchi recomme that the medication release pursues zero order energy with dissemination component.

Table 13: In-vitro release kinetics of the formulation

Formulation	zero-order	First-order	Higuchi	Hixon crowell	Korsmeyer Peppas n
	R2				
F2	0.907	0.941	0.994	0.898	0.506
F6	0.976	0.836	0.980	0.819	0.648
H6	0.940	0.505	0.993	0.755	0.514


Ex-vivodrug permeation:

At first, the saturation of Risperidone arrangement was exposed to dispersion considers. From the outcomes, the total rate measure of Risperidone saturated in 8 h was observed to be 89.88%, while the motion a porousness coefficient of Risperidone was determined to be 0.668 $\text{mg h}^{-1} \text{cm}^{-2}$ a 0.056 cm h^{-1} , indiividually. In light of the in-vitro drug-release (DR), ex-vivo permeation time, swelling a grid dissolutions all things considered, the F2 a F6 were chosen for ex-vivo tranquilize saturation thinks about (Table 5.15 a 5.16). The oral-mucosa of pigs takes after that of people more nearly than some other creature regarding structure a sythesis a in this manner porcine buccal mucosa was chosen for medication penetration examines. The medication pervasion was moderate a Risperidone could saturate through the buccal layer with a without enhancer (PEG 6000) in 8 h.

From the in vitro release a ex vivo pervasion thinks about, F2 detailing considered as improved a utilized for further examinations.

Table 14 : Ex-vivo permeation of optimized formulation(F2)

Time (h)	F2		H6	
	Control	with enhancer	Control	with enhancer
0	0	0	0	0
0.5	8.53±1.21	9.31±1.21	4.19±1.16	6.15±1.15
1	11.68±1.26	12.87±1.24	6.63±1.19	8.29±1.23
2	21.21±1.18	23±1.19	8.75±1.17	11.33±1.25
3	28.81±1.19	31.03±1.21	10.25±1.25	14.95±1.26
4	33.06±2.16	37.37±2.25	12.69±1.23	17.49±1.15
5	41.31±2.25	45.06±2.23	14.19±1.26	21.33±1.13
6	46.56±2.24	49.62±2.19	16.98±1.15	26.66±1.33
7	49.31±1.19	55.31±2.27	18.61±1.02	31.56±1.65
8	55.37±2.26	62.06±2.24	22.45±0.88	36.88±2.82

**Figure 8: Ex-vivo permeation of optimized formulation (F2)****Table 15: Ex-vivo permeation of optimized formulation(F6)**

Time (hr)	Control	with enhancer
0	0	0
0.5	8.12±0.21	9.09±0.21
1	12.9±0.26	14.40±0.24
2	18.81±0.18	22.84±0.19
3	25.51±0.19	27.53±0.21
4	28.93±0.16	30.75±0.25
5	31.81±0.25	34.50±0.23
6	35.25±0.24	39.81±0.19
7	38.87±0.17	46.81±0.24
8	44.68±0.32	56.12±0.22




Figure 9: Ex-vivo permeation of optimized formulation (F6)




Figure 10: Ex-vivo permeation of optimized formulation (H6)

Ex-vivo bio adhesion strength

In-vitro bio adhesion dimensions are performed characteristically for mucoadhesive dosage forms, a the most generally used procedure for the evaluation of buccal tablets is the measurement of adhesive strength. In-vitro bio adhesion for optimized Risperidone buccal tablets was conducted a showed virtuous bio adhesion i.e., work of adhesion 3.88 ± 0.52 mJ, peak detachment force 1.93 ± 0.09 N.

Moisture absorption

Moisture absorption studies evaluated examines assessed the respectability of the detailing upon introduction to dampness. Details F2 were dissolved in 2 hours with 61.54% w/w. At the point when the tablets were situated without the sponsorship film finish swelling pursued by disintegration was watched, showing that the medication release system includes swelling of the polymer at first pursued by drug-release (DR) from the swollen matrix by diffusion.

Stability studies


Results from stability studies indicate that the formulated Risperidone mucoadhesive tablets are stable for a age of 3 months uer two different set of conditions at 25±2oC a 65±5% RH a 40±2oC a 75±5% RH. There were no notable changes were detected hroughout the retro of storing.

Table 16: Stability studies of RISPERIDONE mucoadhesive tablet (F2) at room temperature

Time	Assay		Cumulative % drug-release (DR)		Surface pH	
	25±2oC a 65±5% RH	40±2oC & 75±5%RH	25±2oC a 65±5%RH	40±2oC & 75±5%RH	25±2oC &65±5%RH	40±2oC a 75±5%RH
First day	99.48	99.48	97.6	98.6	6.6	6.6
30 days	99.40	99.30	99.1	97.9	6.6	6.6
60days	99.31	99.2	97.2	97.1	6.6	6.6
90 days	98.5	98.0	98	97.8	6.6	6.6

Comparative bioavailability (BA) study in pigs**Calibration curve of RISPERIDONE in pig serum by HPLC****Table 17: Standard graph of Risperidone in pig serum by HPLC**

Concentration (µg/mL)	Peak area ratio
0	0
0.25	0.08
0.5	0.48
1	0.955
2	2.03
3	3.47
4	4.67
6	7.28
8	9.71

**Figure 11: Calibration curve of Risperidone by HPLC in pig serum**




Figure 12: Chromatogram of RISPERIDONE an internal standard in pig serum

Table 18: Mean serum concentrations of Risperidone buccal tablet (F2) a marketed tablet formulation in pigs after oral administration (mean $\pm$ SD, n=6)

Time (h)	F2 buccal tablet	Marketed tablet
0	0	0
0.5	1.30 $\pm$ 0.23	0.931 $\pm$ 0.21
1	2.87 $\pm$ 0.65	2.43 $\pm$ 0.45
2	4.28 $\pm$ 0.83	1.88 $\pm$ 0.33
3	3.53 $\pm$ 0.66	0.93 $\pm$ 0.27
4	2.18 $\pm$ 0.41	0.63 $\pm$ 0.12
6	1.48 $\pm$ 0.34	0.58 $\pm$ 0.18

8	1.21±0.36	0.47±0.13
12	1.10±0.28	0.06±0.003
24	0.074±0.01	0.02±0.001




Figure 13: Mean serum concentration-time profiles of F2 formulation and marketed tablets in pigs after oral administration (mean±SD, n=6)

Table 19: Pharmacokinetic parameters of Risperidone in pigs after administration of marketed tablet and optimized buccal tablet (F2) (mean±SD, n=6)

Parameter	Marketed Tablet	F2 buccal tablet
C _{max} (µg/mL)	2.43 ± 0.45	4.28 ± 0.83*
T _{max} (h)	0.83 ± 0.25	2.28 ± 0.48*
AUC _{Total} (µg.h/mL)	8.89 ± 1.13	27.50 ± 2.17*
T _{1/2} (h)	3.45 ± 0.31	3.94 ± 0.74
MRT (h)	4.51 ± 1.24	6.98 ± 0.37#

* - statistically significant at $p < 0.001$ # - statistically significant at $p < 0.01$ compared with marketed tablet.

The bioavailability (BA) study of optimized buccal tablet (F2) and marketed tablet (immediate release) formulation were conducted in pigs. The mean serum concentration-time profiles of formulations were given in Table 5.20 and Figure 5.15. The pharmacokinetic (PK) parameters of the study were represented in Table 4.17. From the results, the C_{max}, T_{max} of the F2 and marketed formulations were found to be 4.28 ± 0.83 and 2.43 ± 0.45 µg/mL; 2.28 ± 0.48 and 0.83 ± 0.25 h, respectively. These C_{max}, T_{max} parameters are twice as compared to that of marketed formulations and were statistically significant at $p < 0.01$.

There was no statistically significant change in the half-life observed (3.94 ± 0.74 and 3.45 ± 0.31 h for F2 and marketed formulation). But, in case of MRT significant changes were observed ($p < 0.01$) in F2 (6.98 ± 0.37 h) and marketed (4.51 ± 1.24 h) formulations, respectively.

AUC is the main parameter to depict the bioavailability (BA) of the formulation. In this, the AUC_{total} of the F2 buccal and marketed formulation was found to be 27.50 ± 2.17 and 8.89 ± 1.13 µg.h/mL, respectively ($p < 0.001$). There was 3.09-fold enhancement in bio-adhesion in the oral BA of Risperidone from buccal tablet when related with immediate release marketed formulation. This may be ascribed to the peroral organization, where Risperidone is promptly accessible for assimilation; despite the fact that, the buccal plan, practically equivalent to a grid detailing, has Risperidone encompassed in a polymeric network of HPMC K4M. This may cause a slight block in medication release/disintegration from the polymeric network before being promptly accessible for assimilation.

Conclusion

The most extreme wavelength of Risperidone was observed to be 264 nm by filtering in the UV-unmistakable scope of 200–400 nm. The dissolvability of Risperidone was more in the pH 6.8 phosphate-cushion than 0.1N HCl a refined water, subsequently, pH 6.8 phosphate-cradle chose as disintegration media. From the DSC considers, there was no collaboration among medication excipients utilized for the advance bio-adhesive of definition were watched. The buccal tablets of Risperidone were set up by direct pressure strategy utilizing HPMC K4M a carbopol as mucoadhesive polymers. The tablets were compacted by utilizing 6 mm level confronted punches on turning station punching machine. Prior to pressure, the mix was exposed to stream properties. From the outcomes, the mix demonstrated great free streaming property. The estimations of weight variety a thickness of the tablets were observed to be inside the points of confinement of regular oral tablets expressed in the Iian Pharmacopeia. The mass exteed from 172 to 178 mg. Thickness of the tablets fluctuated from 2.22 mm to 2.34 mm. Hardness of the tablets was in the range 3 to 3.5 kg/cm². The mass, thickness a hardness of every single compacted tablet were inside the cutoff points according to USP. The medication content ran from 95.44 to 102.46. The friability went from 0.21 to 0.53. Friability a test of every single compacted tablet were inside the cutoff points according to USP. Every one of the plans demonstrated great swelling list in the scope of 11 to 71%. Plan F6 containing carbopol had indicated most extreme swelling file. The surface pH of all plans was inside a scope of 6.2 to 7.0, near unbiased pH. These outcomes uncover that every one of the plans give a worthy pH in the scope of salivary pH (6.6 to 7.0). From the ex-vivo home time, as the convergence of polymer expand, the maintenance time expaed. This test mirrors the glue limit of polymers utilized in definitions. The release rate of Risperidone diminished with expaing centralization of HPMC K4M from F1 to F4 a release rate diminished with expaing the focus carbopol from F5 to F8. Definition F2 created with HPMC K4M released 99.62±2.24% in 6 h. The higher R² values for Zero order a Higuchi recommend that the medication release pursues zero order energy with dispersion instrument. In view of the in-vitro sedate release, ex-vivo home time, swelling a network disintegrations everything being equal, the F2 a F6 were chosen for ex-vivo medicate pervasion poers Initially, the saturation of Risperidone arrangement was exposed to dissemination thinks about. From the outcomes, the combined rate measure of Risperidone saturated in 8 h was observed to be 89.88%, while the transition a penetrability coefficient of Risperidone were determined to be 0.668 mg h⁻¹ cm⁻² a 0.056 cm h⁻¹, individually. From the in vitro release a ex vivo penetration contemplates, F2 detailing considered as streamlined a utilized for further examinations. In vitro bio adhesion for upgraded Risperidone buccal tablets was led a showed great bio adhesion i.e., work of attachment 3.88 ±0.52 mJ, crest separation drive 1.93±0.09 N Dampness ingestion contemplates assessed the uprightness of the plan upon presentation to dampness. Definitions F2 were dissolved in 2 hours with 61.54% w/w.

Souness poers demonstrate that the defined Risperidone mucoadhesive tablets are steady for a time of 3 months uer 2 distinct conditions at 25±2oc a 65±5%RH a 40±2oc a 75±5%RH. There were no momentous changes were seen amid the time of capacity. The bioavailability (BA) investigation of enhanced buccal tablet (F2) a promoted tablet (quick release) plan (Nepresol®) were led in pigs. PK parameters were determined by Kinetica programming. The information was exposed to study unpaired t-test by utilizing Graph Pad Prism (reition 5.0. 2015). From the pharmacokinetic (PK) parameters results, the C_{max}, T_{max} of the F2 a advertised plans were fou to be 4.28 ± 0.83 a 2.43 ±0.45 µg/mL; 2.28 ± 0.48 a 0.83 ± 0.25 h, iividually. These C_{max} T_{max} parameters are twice when contrasted with thatof showcased details a were factually huge at dimension of p<0.01. There was no factually noteworthy change in the half-life was watched (3.94 ±0.74 a 3.45 ±0.31 h for F2 a showcased detailing). However, if there should arise an occurrence of MRT critical changes were watched (p<0.01) in F2 (6.98 ±0.37 h) a showcased (4.51±1.24 h) plans, separately.

AUC is the primary parameter to delineate the bioavailability (BA) of the detailing. In this, the AUC total of the F2 buccal a advertised plan was observed to be 27.50 ± 2.17 a 8.89 ± 1.13 µg.h/mL, separately (p<0.001). There was 3.09-folds improvement in the oral bioavailability (BA) of RISPERIDONE from buccal tablet when contrasted a quick release advertised detailing. This may be ascribed to the peroral organization, where RISPERIDONE is promptly accessible for retention; despite the fact that, the buccal definition, closely resembling a network plan, has RISPERIDONE encompassed in a polymeric lattice of HPMC K4M. This may cause a slight deterrent in medication release/disintegration from the polymeric network before being promptly accessible for ingestion.

References

1. Affi EA, Mahmoud MS, El-Samality NN.(2006),Increasing bioavailability (BA) of silymarin using a buccal liposomal delivery. *Int J Pharma.* 308:140-148.
2. AgarwalV,Mishra. B. (1999), Design, development a biopharmaceutical properties of buccoadhesive compacts of pentazocine. *Drug DevI Pharm.*; 25:701– 709
3. Agbaba D, Vucicevic K, Marinkovic V.(2004),Determination of nisoldipine a its impurities in pharmaceuticals. *Chromatographia.*60:223-227.
4. Ahuja A, Dogra M, Agarwal SP.(1995),Development of buccaltabets of diltiazem hydrochloride. *Iian J Pharm Sci.*; 57:26– 30
5. Ahuja A, Khar RK, Ali J.(1997) Mucoadhesive drug delivery systems.*Drug DevI Pharm.*; 23(5):489–517.
6. Akbari J, Nokhodchi A, Farid D, Adrangui M, Siahi-Shadbad MR, Saeedi M.

7. (2004), Development a evaluation of buccoadhesivepropranolol hydrochloride tablet formulations: Effect of fillers, *IL Farmaco*; 59:155– 161
8. Allen A, in: J.G. Forte (Ed.). (1989), *Habook of Physiology - the Gastrointestinal Physiology, Salivary, Gastric a Hepatobiliary Secretions*. American Physiological Society, Bethesda MD; 3(6):359–382.
9. Allen C, Maysinger D, Eisenberg A.(1999), Nano-engineering block copolymer aggregates for drug delivery, *Colloids Surf., B. Biointerfaces Spec. Issue, Polym Micelles Biol Pharma.*; 16:3–27.
10. Alur RISPERIDONE, Pather SI, Mitra AK, Johnston TP. (1999), Transmucosal sustained delivery of chlorpheniramine maleate in rabbits using a novel natural mucoadhesive gum as an excipient in buccal tablets. *Int J Pharm*;188:1-10.
11. Amal Kumar Bayopadhyay, Pulak Kumar Metia.(2008), In vitro evalution of novel mucoadhesive buccal tablets of oxytocine diospyros peregrina fruits mucilage. *The pharmaceutical society japan*;128: 603-609
12. Aers R, Merkle HP.(1989), Evaluation of laminated muco-adhesivepatches for Buccal drug delivery (BDD). *Int J Pharm*;49:231–240.
13. Ankarao A, Babu Rao Ch a Devanna K.(2010), Formulation a Evaluation of Buccoadhesive Bilayered Tablets of Carvedilol. *An International Journal of Advances In Pharmaceutical Sciences*. 1(1). pp.71-76
14. Anlar, S., Capan, Y., Guven, O., Gogus, A., Dlakara, T. a Hincal, A. A. (1994), Formulation a in-vitro - in-vivo evaluation of buccoadhesive morphine sulfate tablets, *Pharm. Res.* 11: 231-236.
15. Arya RK et al.,(2011), Development a Evaluation of Mucoadhesive Buccal Tablets of Salbutamol Sulphate. *IJRP*. 2(1), pp. 159-162.
16. Audus KL. Oral-mucosal drug delivery, in: Rathbone MJ (Ed.), *Marcel Dekker*, New York, 101–119.
17. Aungst A.(1994), Permeability a metabolism as barriers to transmucosal delivery of peptides a proteins: Hsieh DS (Ed.), *Drug Permeation Enhancebio-adhesive.Theory a Applications*, Marcel Dekker, New York, 323-343.
18. Barichello JM, Morishita M, Takayama K, Chiba Y, Tokiwa S, Nagai T. (1999) ,Enhanced rectal absorption of insulinloadedPluronicR F-127 gels containing unsaturated fatty acids. *Int J Pharm*.183:125–132.
19. Batchelor H.(2004), Novel bio-adhesive formulations in drug delivery, *The Drug Delivery Companies Report Autumn/Winter*. Pharma Ventures Ltd.
20. Behera Basanta Kumar, RanjitMohapatra, Sunit Kumar Sahu, VikramViswajit Mishra, Akula Santoshkumar.(1988), Mucoadhesive Buccal drug delivery (BDD) systems containing rosiglitazone maleate for treatment of type ii diabetes: formulation design a in –vitro evaluation. *World Journal of Pharmaceutical research*.1(3), 689-704.
21. Bottenberg P, Cleymaet R, Muynek CD, Remon JP, Coomans D, Slop D. (1991),Development a testing of bio-adhesive, fluoride-containing slow-release tablets for oral use. *J Pharm Pharmacol*;43: 457-464.
22. Bremecker K.D., Strempel H., Klein G., (1984), Novel concept for a mucosal adhesive ointment. *J.Pharm.Sci*, 73, 548-552.
23. Brun PPHL, Fox PLA, Vries MED, Bodde HE.(1989),In vitro penetrationof some β adrenoreceptor blocking drugs through porcine buccal mucosa. *Int J Pharm.*; 49: 141–145.
24. Cafaggi, S., Leardi, R., Parodi, B., Caviglioli, G., Russo, E. a Bignardi, G. (2005), Preparation a Evaluation of a Chitosan Salt-ploxamer 407 Based Matrix for Buccal drug delivery (BDD). *J. Control. Rel*102, 159-69
25. Carmen Remun~a'N-Lo'Pez et al. (1998), Design a Evaluation of Chitosan / Ethyl cellulose Mucoadhesive Bilayered Devices for Buccal drug delivery (BDD). *Journal of Controlled-release (CR)*.55. pp. 143–152.